| Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. | |
| | |
MedLine Citation:
|
PMID: 20421882 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Conventionally, atherogenic dyslipidemias have been defined by elevated levels of triglyceride and/or LDL cholesterol. However, cholesterol and triglycerides are not metabolically and physically independent entities. Rather, they are constituents of the atherogenic apolipoprotein B (apoB) particles, which differ in their origin and their metabolic function. Moreover, the risk of vascular disease is not related to the plasma concentration of cholesterol or triglyceride per se, but to the number, composition and size of the apoB particles, within which the cholesterol and triglycerides are contained. After all, the entire apoB particle--rather than individual cholesterol or triglyceride molecules--enters and is trapped within the arterial wall, and this particle initiates and sustains the process that results in atherosclerosis. Accordingly, we suggest a change of name and focus from dyslipidemias to dyslipoproteinemias. Virtually all the atherogenic apoB dyslipoproteinemias can be specifically identified on the basis of plasma levels of cholesterol, triglyceride and apoB. Not only does this enable an accurate diagnosis in the individual, but the major familial dyslipoproteinemias can be identified as well. Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids. |
| | |
Authors:
|
Allan Sniderman; Patrick Couture; Jacqueline de Graaf |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-04-27 |
Journal Detail:
|
Title: Nature reviews. Endocrinology Volume: 6 ISSN: 1759-5037 ISO Abbreviation: Nat Rev Endocrinol Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-26 Completed Date: 2010-09-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101500078 Medline TA: Nat Rev Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 335-46 Citation Subset: IM |
Affiliation:
|
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Room H7.22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada. allansniderman@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Apolipoproteins B / blood* Atherosclerosis / etiology Cholesterol / blood Chylomicron Remnants / blood Chylomicrons / blood Dyslipidemias / blood, complications, diagnosis*, therapy* Humans Lipoproteins / antagonists & inhibitors, blood Lipoproteins, VLDL / blood Terminology as Topic Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoproteins B; 0/Chylomicron Remnants; 0/Chylomicrons; 0/Lipoproteins; 0/Lipoproteins, VLDL; 0/Triglycerides; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Are anti-C1q antibodies different from other SLE autoantibodies?
Next Document: Immunity, thyroid function and pregnancy: molecular mechanisms.